FY26 UDO initiative
Ended Awarded Last action
- Contract number
- 75N91018F00066
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $14,845,322
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 56% obligated
-
- $14,845,322.08 Current, with exercised options
- $26,659,044.08 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$3,163 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $465,966 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $5,897,683 | |
| Exercise an Option | $1,043,611 | |
| Original award | $7,441,225 |
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on September 30, 2018, with a ceiling value of $26.659 million under a cost-plus-fixed-fee pricing model for anti-HIV broadly neutralizing monoclonal antibodies for AMP trials as part of the FY26 UDO Initiative.
Place of performance is Frederick, MD. The order's ultimate completion date is September 29, 2023.
Service Contract Inventory data shows actual government-invoiced labor across four fiscal years: FY2020 invoiced $1.2 million; FY2021 invoiced $1.4 million (1.0 FTEs, 2,076 contractor hours); FY2022 invoiced $5 million (16.5 FTEs, 34,274 contractor hours); FY2023 invoiced $1.5 million (2.0 FTEs, 4,185 contractor hours). Derived government-paid hourly rates were $670.36/hr in FY2021, $145.78/hr in FY2022, and $369.12/hr in FY2023. In FY2023, the prime self-performed all reported hours with no subcontractor engagement.
Quick answers
Who was awarded contract 75N91018F00066?
75N91018F00066 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2018.
How much is contract 75N91018F00066 worth?
The government has obligated $14,845,322 on 75N91018F00066. Its potential value, with all options, is $26,659,044.
Which agency awarded contract 75N91018F00066?
National Cancer Institute (National Institutes of Health) awarded 75N91018F00066, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91018F00066 an order under another contract?
Yes. 75N91018F00066 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract 75N91018F00066 competed?
The extent of competition for 75N91018F00066 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award